View Future GrowthSofWave Medical 過去の業績過去 基準チェック /46SofWave Medicalは、平均年間35.3%の収益成長を遂げていますが、 Medical Equipment業界の収益は、年間 成長しています。収益は、平均年間14.8% 33.1%収益成長率で 成長しています。 SofWave Medicalの自己資本利益率は22.5%であり、純利益率は8.2%です。主要情報35.26%収益成長率35.61%EPS成長率Medical Equipment 業界の成長8.90%収益成長率33.12%株主資本利益率22.46%ネット・マージン8.24%前回の決算情報31 Mar 2026最近の業績更新お知らせ • Mar 10SofWave Medical Ltd. to Report Q4, 2025 Results on Mar 17, 2026SofWave Medical Ltd. announced that they will report Q4, 2025 results on Mar 17, 2026お知らせ • Oct 20SofWave Medical Ltd. to Report Q3, 2025 Results on Nov 04, 2025SofWave Medical Ltd. announced that they will report Q3, 2025 results on Nov 04, 2025お知らせ • Jul 16SofWave Medical Ltd. to Report Q2, 2025 Results on Aug 05, 2025SofWave Medical Ltd. announced that they will report Q2, 2025 results on Aug 05, 2025すべての更新を表示Recent updatesお知らせ • Mar 19SofWave Medical Ltd., Annual General Meeting, Apr 23, 2026SofWave Medical Ltd., Annual General Meeting, Apr 23, 2026. Location: co. offices, Israelお知らせ • Mar 10SofWave Medical Ltd. to Report Q4, 2025 Results on Mar 17, 2026SofWave Medical Ltd. announced that they will report Q4, 2025 results on Mar 17, 2026お知らせ • Jan 07SofWave Medical Ltd. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2025SofWave Medical Ltd. provided earnings guidance for the fourth quarter and full year ended December 31, 2025. for the quarter, the company expects total between $28.6 million and $28.9 million, as compared to approximately $18.3 million in the same period last year, reflecting an increase of approximately 57% compared to the same period last year. for the year, revenue is expected to total between $87.3 million and $87.6 million, as compared to approximately $59.7 million in the same period last year, reflecting an increase of approximately 46% compared to the same period last year.お知らせ • Oct 20SofWave Medical Ltd. to Report Q3, 2025 Results on Nov 04, 2025SofWave Medical Ltd. announced that they will report Q3, 2025 results on Nov 04, 2025お知らせ • Sep 04Sofwave Medical Ltd. Receives FDA, Pre-market Clearance for Pure Impact VIP Standalone EMS Device for Comprehensive Multi-Body Area Muscle Strengthening and FirmingSofwave Medical Ltd. announced that the Company has received 510(k) premarket notification clearance from the U.S. Food and Drug Administration (FDA). This clearance expands the Pure Impact™? product line further via the launch of a standalone EMS Device branded Pure Impact VIP™?. The Pure Impact VIP™? is designed as a standalone system that can be delegated and administered by staff using a simple and intuitive procedure.お知らせ • Aug 12Migdal Insurance and Financial Holdings Ltd. (TASE:MGDL) acquired 3.96% stake in SofWave Medical Ltd. (TASE:SOFW) for ILS 37.6 million.Migdal Insurance and Financial Holdings Ltd. (TASE:MGDL) acquired 3.96% stake in SofWave Medical Ltd. (TASE:SOFW) for ILS 37.6 million on August 7, 2025. A cash consideration valued at ILS 27.12 per share will be paid by Migdal Insurance. Migdal Insurance and Financial Holdings Ltd. (TASE:MGDL) completed the acquisition of 3.96% stake in SofWave Medical Ltd. (TASE:SOFW) on August 7, 2025.お知らせ • Jul 16SofWave Medical Ltd. to Report Q2, 2025 Results on Aug 05, 2025SofWave Medical Ltd. announced that they will report Q2, 2025 results on Aug 05, 2025お知らせ • Apr 25Sofwave’S Lifthd Body Contouring Applicator to Debut At the 44Th Annual Meeting of the American Society for Laser Medicine and Surgery (Aslms) 2025SofWave Medical Ltd. announced activities around the official launch of the liftHD high density body contouring handpiece at the 44th Annual Meeting of the American Society for Laser Medicine and Surgery (ASLMS) 2025 on energy-based medicine and science being held at the Orange County convention Center in Orlando, Florida, from April 24- 26, 2025. Sofwave’s onsite exhibition booth will be active throughout the event, showcasing the liftHD non-invasive aesthetic body contouring applicator as well as the Sofwave family of SUPERB™ and Pure Impact™ product lines. The new body contouring applicator benefits patients by utilizing the same precise SUPERB™ pulse technology as with the SUPERB™ line of treatments but with broader, higher density controlled thermal zones resulting in less pulses per treatment, thereby reducing treatment time by ~40%. The liftHD applicator by Sofwave is the Company’s newest applicator and provides the opportunity to deliver next generation non-invasive aesthetic body treatments which improve cellulite and skin laxity appearance to achieve SUPERB results beyond the face. This body applicator’s user-friendly, ergonomic design was specifically made to deliver fast, efficient, comfortable treatments. SUPERB™ Treatment Technology is Not Only Different But Better than the Competition.Precise depth control – The thermal treatment zone is precisely placed between 0.5mm and 1.8 mm to stimulate natural healing and collagen, elastin, and hyaluronic acid production. Optimized Energy Delivery - Optimal dermal timulation is achieved by parallel heating the dermis to a temperature of 149-158°F for a controlled, predictable, and dermally selective treatment outcome.Unique Broad Tissue Coverage - Seven parallel beam transducers simultaneously create large, controlled 3D cylindrical thermal zones with each pulse, resulting in optimal treatment coverage in just one 30–45-minute treatment. In addition, clinicians continue to expand the body of clinical evidence and case studies which strongly supporting the benefits of the Sofwave™ family of products and treatments.お知らせ • Apr 21Sofwave Medical Ltd.'s SUPERB™ Non-Invasive Skin Treatment Technology Receives Regulatory Clearance in Japan Significantly Expanding its Coverage of the APAC RegionSofwave Medical Ltd. announced that Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has granted the Company approval to commercially market Sofwave's SUPERB™? Technology. Market approval in Japan further extends Sofwave's sales reach in the APAC territories, which now comprises major regional medical aesthetic device markets, including Japan, Australia, Taiwan, and South Korea.お知らせ • Mar 10SofWave Medical Ltd., Annual General Meeting, Apr 15, 2025SofWave Medical Ltd., Annual General Meeting, Apr 15, 2025. Location: cpc buileding, yokneaml, Israelお知らせ • Jan 14Sofwave Medical Provides Earnings Guidance for Fourth Quarter and Full Year 2024Sofwave Medical Provided Earnings Guidance for fourth quarter and full year 2024. For the quarter, the company expects revenue to total between $18.2 million and $18.4 million, as compared to approximately $15.3 million in the same period last year, reflecting an increase of approximately 20% compared to the same period last year. For the full year 2024, the company expects revenue to total between $59.5 million and $59.7 million, as compared to approximately $50.3 million in the same period last year, reflecting an increase of approximately 19% compared to the same period last year.収支内訳SofWave Medical の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:SOFW.F 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Mar 26958491331 Dec 25885461330 Sep 25771441230 Jun 2569-2421131 Mar 2563-5411131 Dec 2460-5381130 Sep 2457-4361130 Jun 2455-4351031 Mar 2453-5341131 Dec 2350-8341130 Sep 2349-12351230 Jun 2345-15351331 Mar 2340-18341331 Dec 2236-20311230 Sep 2228-18261230 Jun 2225-15231131 Mar 2222-1119931 Dec 2122-717830 Sep 2118-714730 Jun 2114-610631 Mar 219-97531 Dec 204-125531 Dec 190-313質の高い収益: SOFW.Fは 高品質の収益 を持っています。利益率の向上: SOFW.F過去に利益を上げました。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: SOFW.F過去 5 年間で収益を上げており、収益は年間35.3%増加しています。成長の加速: SOFW.Fは昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。収益対業界: SOFW.F昨年収益を上げたため、昨年の収益成長をMedical Equipment業界 ( 15.7% ) と比較することは困難です。株主資本利益率高いROE: SOFW.Fの 自己資本利益率 ( 22.5% ) は 高い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YHealthcare 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/07 20:28終値2026/05/28 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋SofWave Medical Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Mar 10SofWave Medical Ltd. to Report Q4, 2025 Results on Mar 17, 2026SofWave Medical Ltd. announced that they will report Q4, 2025 results on Mar 17, 2026
お知らせ • Oct 20SofWave Medical Ltd. to Report Q3, 2025 Results on Nov 04, 2025SofWave Medical Ltd. announced that they will report Q3, 2025 results on Nov 04, 2025
お知らせ • Jul 16SofWave Medical Ltd. to Report Q2, 2025 Results on Aug 05, 2025SofWave Medical Ltd. announced that they will report Q2, 2025 results on Aug 05, 2025
お知らせ • Mar 19SofWave Medical Ltd., Annual General Meeting, Apr 23, 2026SofWave Medical Ltd., Annual General Meeting, Apr 23, 2026. Location: co. offices, Israel
お知らせ • Mar 10SofWave Medical Ltd. to Report Q4, 2025 Results on Mar 17, 2026SofWave Medical Ltd. announced that they will report Q4, 2025 results on Mar 17, 2026
お知らせ • Jan 07SofWave Medical Ltd. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2025SofWave Medical Ltd. provided earnings guidance for the fourth quarter and full year ended December 31, 2025. for the quarter, the company expects total between $28.6 million and $28.9 million, as compared to approximately $18.3 million in the same period last year, reflecting an increase of approximately 57% compared to the same period last year. for the year, revenue is expected to total between $87.3 million and $87.6 million, as compared to approximately $59.7 million in the same period last year, reflecting an increase of approximately 46% compared to the same period last year.
お知らせ • Oct 20SofWave Medical Ltd. to Report Q3, 2025 Results on Nov 04, 2025SofWave Medical Ltd. announced that they will report Q3, 2025 results on Nov 04, 2025
お知らせ • Sep 04Sofwave Medical Ltd. Receives FDA, Pre-market Clearance for Pure Impact VIP Standalone EMS Device for Comprehensive Multi-Body Area Muscle Strengthening and FirmingSofwave Medical Ltd. announced that the Company has received 510(k) premarket notification clearance from the U.S. Food and Drug Administration (FDA). This clearance expands the Pure Impact™? product line further via the launch of a standalone EMS Device branded Pure Impact VIP™?. The Pure Impact VIP™? is designed as a standalone system that can be delegated and administered by staff using a simple and intuitive procedure.
お知らせ • Aug 12Migdal Insurance and Financial Holdings Ltd. (TASE:MGDL) acquired 3.96% stake in SofWave Medical Ltd. (TASE:SOFW) for ILS 37.6 million.Migdal Insurance and Financial Holdings Ltd. (TASE:MGDL) acquired 3.96% stake in SofWave Medical Ltd. (TASE:SOFW) for ILS 37.6 million on August 7, 2025. A cash consideration valued at ILS 27.12 per share will be paid by Migdal Insurance. Migdal Insurance and Financial Holdings Ltd. (TASE:MGDL) completed the acquisition of 3.96% stake in SofWave Medical Ltd. (TASE:SOFW) on August 7, 2025.
お知らせ • Jul 16SofWave Medical Ltd. to Report Q2, 2025 Results on Aug 05, 2025SofWave Medical Ltd. announced that they will report Q2, 2025 results on Aug 05, 2025
お知らせ • Apr 25Sofwave’S Lifthd Body Contouring Applicator to Debut At the 44Th Annual Meeting of the American Society for Laser Medicine and Surgery (Aslms) 2025SofWave Medical Ltd. announced activities around the official launch of the liftHD high density body contouring handpiece at the 44th Annual Meeting of the American Society for Laser Medicine and Surgery (ASLMS) 2025 on energy-based medicine and science being held at the Orange County convention Center in Orlando, Florida, from April 24- 26, 2025. Sofwave’s onsite exhibition booth will be active throughout the event, showcasing the liftHD non-invasive aesthetic body contouring applicator as well as the Sofwave family of SUPERB™ and Pure Impact™ product lines. The new body contouring applicator benefits patients by utilizing the same precise SUPERB™ pulse technology as with the SUPERB™ line of treatments but with broader, higher density controlled thermal zones resulting in less pulses per treatment, thereby reducing treatment time by ~40%. The liftHD applicator by Sofwave is the Company’s newest applicator and provides the opportunity to deliver next generation non-invasive aesthetic body treatments which improve cellulite and skin laxity appearance to achieve SUPERB results beyond the face. This body applicator’s user-friendly, ergonomic design was specifically made to deliver fast, efficient, comfortable treatments. SUPERB™ Treatment Technology is Not Only Different But Better than the Competition.Precise depth control – The thermal treatment zone is precisely placed between 0.5mm and 1.8 mm to stimulate natural healing and collagen, elastin, and hyaluronic acid production. Optimized Energy Delivery - Optimal dermal timulation is achieved by parallel heating the dermis to a temperature of 149-158°F for a controlled, predictable, and dermally selective treatment outcome.Unique Broad Tissue Coverage - Seven parallel beam transducers simultaneously create large, controlled 3D cylindrical thermal zones with each pulse, resulting in optimal treatment coverage in just one 30–45-minute treatment. In addition, clinicians continue to expand the body of clinical evidence and case studies which strongly supporting the benefits of the Sofwave™ family of products and treatments.
お知らせ • Apr 21Sofwave Medical Ltd.'s SUPERB™ Non-Invasive Skin Treatment Technology Receives Regulatory Clearance in Japan Significantly Expanding its Coverage of the APAC RegionSofwave Medical Ltd. announced that Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has granted the Company approval to commercially market Sofwave's SUPERB™? Technology. Market approval in Japan further extends Sofwave's sales reach in the APAC territories, which now comprises major regional medical aesthetic device markets, including Japan, Australia, Taiwan, and South Korea.
お知らせ • Mar 10SofWave Medical Ltd., Annual General Meeting, Apr 15, 2025SofWave Medical Ltd., Annual General Meeting, Apr 15, 2025. Location: cpc buileding, yokneaml, Israel
お知らせ • Jan 14Sofwave Medical Provides Earnings Guidance for Fourth Quarter and Full Year 2024Sofwave Medical Provided Earnings Guidance for fourth quarter and full year 2024. For the quarter, the company expects revenue to total between $18.2 million and $18.4 million, as compared to approximately $15.3 million in the same period last year, reflecting an increase of approximately 20% compared to the same period last year. For the full year 2024, the company expects revenue to total between $59.5 million and $59.7 million, as compared to approximately $50.3 million in the same period last year, reflecting an increase of approximately 19% compared to the same period last year.